The roles of cell cycle proteins in regulating the tumor immune microenvironment

Qingbo Zhu1, Xiaoli Wei1, Ziting Qu1

  • 1Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230022, China.

Genes & Diseases
|October 20, 2025
PubMed

Insights

Cell cycle proteins regulate tumor growth and immunity by affecting immune cells within the tumor immune microenvironment (TIME). Targeting these proteins offers a promising avenue for future cancer immunotherapy strategies.

Area of Science:

  • Immunology
  • Oncology
  • Molecular Biology

Background:

  • Cell cycle proteins traditionally regulate tumor cell proliferation.
  • Emerging evidence indicates their role extends to modulating the tumor immune microenvironment (TIME).
  • This dual function impacts overall tumor immunity.

Purpose of the Study:

  • To review the mechanisms by which cell cycle regulatory proteins influence the TIME.
  • To highlight the significance of these proteins in tumor immunity.
  • To identify potential therapeutic targets for cancer immunotherapy.

Main Methods:

  • Literature review of recent studies on cell cycle proteins and tumor immunity.
  • Analysis of mechanisms linking cell cycle proteins to immune cell function and factors within the TIME.
  • Synthesis of current knowledge on the role of cell cycle proteins in antitumor responses.

Main Results:

  • Cell cycle proteins directly impact immune cells and soluble factors within the TIME.
  • These proteins are critical regulators of the complex tumor immune landscape.
  • Dysregulation of cell cycle proteins contributes to immune evasion and tumor progression.

Conclusions:

  • Cell cycle regulatory proteins are key players in orchestrating tumor immunity.
  • Targeting cell cycle proteins presents a novel strategy for enhancing antitumor immunotherapy.
  • Further research into these mechanisms could lead to next-generation cancer treatments.

Related Concept Videos

The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.6K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
38.2K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.7K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.6K